Market research
DC8.F DURECT Corporation
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 6.5
- Dividend yield
- 0.0%
- Beta
- 1.17
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 6.5
- Dividend yield
- 0.0%
- Beta
- 1.17
About
About DURECT Corporation
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the DC8.F discussion.
5 years, 5 months ago
DURECT Corporation is currently in a long term downtrend where the price is trading 23.4% below its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.2.
DURECT Corporation's total revenue sank by 111.1% to $-1M since the same quarter in the previous year.
Its net income has increased by 203.0% to $4M since the same quarter in the previous year.
Finally, its free cash flow fell by 315.4% to $-8M since the same quarter in the previous year.
Based on the above factors, DURECT Corporation gets an overall score of 2/5.